Kenvue Inc. (FRA:J4D)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.85B -11.4% |
| Revenue (ttm) | 13.27B -0.1% |
| Net Income | 1.41B +53.6% |
| EPS | 0.73 +52.3% |
| Shares Out | n/a |
| PE Ratio | 22.62 |
| Forward PE | 15.59 |
| Dividend | 0.71 (4.31%) |
| Ex-Dividend Date | May 13, 2026 |
| Volume | n/a |
| Open | 16.19 |
| Previous Close | 16.10 |
| Day's Range | 16.19 - 16.43 |
| 52-Week Range | 11.83 - 19.87 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Kenvue
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial numbers in USD Financial StatementsNews
Kenvue price target raised to $20 from $18 at UBS
UBS raised the firm’s price target on Kenvue (KVUE) to $20 from $18 and keeps a Neutral rating on the shares.
Appeals court revives autism suits against Kenvue’s Tylenol, Bloomberg says
A New York federal appeals court revived lawsuits that claim Kenvue (KVUE) concealed alleged risks that Tylenol could cause autism in children whose mothers took the pain medication while pregnant,…
Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says
11:23 EDT Appeals court rules Kenvue (KVUE) must face Tylenol autism claims, Bloomberg says
US appeals court revives private lawsuits linking Tylenol to autism, ADHD
A federal appeals court on Monday revived hundreds of private lawsuits against Kenvue and many pharmacies and retailers, alleging that the Tylenol painkiller causes autism and attention deficit...
Kimberly-Clark price target raised to $121 from $115 at Piper Sandler
Piper Sandler raised the firm’s price target on Kimberly-Clark (KMB) to $121 from $115 and keeps an Overweight rating on the shares. Upside from Kimberly-Clark’s Kenvue (KVUE) deal doesn’t really…
Kenvue Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of 12 directors, approval of executive compensation, and ratification of the auditor. All proposals passed, with final results to be filed in a Form 8-K.
Kenvue Earnings release: Q1 2026
Kenvue released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Kenvue Quarterly report: Q1 2026
Kenvue has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark
Tylenol-maker Kenvue on Thursday beat Wall Street estimates for first-quarter revenue and profit helped by strong sales in its skin health and beauty brands.
Kenvue reports Q1 adjusted EPS 32c, consensus 26c
Reports Q1 revenue $3.91B, consensus $3.85B. “Our year is off to an encouraging start, as our continued efforts to strengthen the business and sharpen execution resulted in delivering net and…
Kenvue Reports First Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal first quarter ended March 29, 2026. “Our year is off to an encouraging start, as our continued ...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is pa...
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clar...
Kimberly-Clark Details Structure, Leadership Team Following Kenvue Deal
The combined company, which will include consumer brands such as Kleenex tissues and Huggies diapers as well as over-the-counter products including Tylenol and Listerine, will operate under four geogr...
Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal
Kimberly-Clark on Wednesday said its chief financial officer, Nelson Urdaneta, will become the finance chief of the combined company it will create after completing its $40-billion acquisition of Ty...
Kimberly-Clark announces organizational structure after acquisition of Kenvue
Kimberly-Clark (KMB) announced the organizational structure and key leadership that will become effective upon completion of its pending acquisition of Kenvue (KVUE). After close, the combined company...
Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership
DALLAS, April 15, 2026 /PRNewswire/ -- Kimberly‑Clark Corporation (NASDAQ: KMB) today announced the organizational structure and key leadership that will become effective upon completion of its pendin...
Kenvue price target lowered to $19 from $20 at Citi
Citi lowered the firm’s price target on Kenvue (KVUE) to $19 from $20 and keeps a Neutral rating on the shares. The firm adjusted targets in the beverages, household and…
Kenvue price target lowered to $18 from $19 at Barclays
Barclays lowered the firm’s price target on Kenvue (KVUE) to $18 from $19 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the consumer staples…
Tylenol in pregnancy not linked with autism, Danish study finds
The use of Tylenol by women during pregnancy was not associated with autism in their children, according to results of a nationwide study in Denmark published on Monday.
Kenvue Proxy statement: Proxy filing
Kenvue filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Kenvue Proxy statement: Proxy filing
Kenvue filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Kenvue price target lowered to $18 from $19 at UBS
UBS lowered the firm’s price target on Kenvue (KVUE) to $18 from $19 and keeps a Neutral rating on the shares. The firm thinks Q1 results for much of the…